



# Balfour Capital Group McKesson Corporation

McKesson Corporation is a leading global healthcare company that distributes pharmaceuticals, medical supplies, and provides healthcare technology solutions. The company partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver products and services that make quality care more accessible and affordable.

## 1. Top 5 Competitors

McKesson's primary competitors in the healthcare distribution and services sector include:

1. Cencora Inc. (formerly AmerisourceBergen)
2. Cardinal Health Inc.
3. Henry Schein Inc.
4. Owens & Minor Inc.
5. athenahealth

## 2. Largest Institutional Shareholders

As of recent filings, McKesson's largest institutional shareholders are:

- The Vanguard Group, Inc.
- BlackRock, Inc.
- State Street Corporation
- Massachusetts Financial Services Co.
- JPMorgan Chase & Co.

Institutional investors collectively own approximately 46% of McKesson's outstanding shares.

## 3. Management Team

Key members of McKesson's executive leadership include:

- Brian Tyler – Chief Executive Officer
- Joan Eliasek – President, McKesson Canada
- Francisco Fraga – EVP, Chief Information & Technology Officer
- Nimesh Jhaveri – EVP & Chief Impact Officer
- Kirk Kaminsky – President, U.S. Pharmaceutical
- Kevin Kettler – President, Prescription Technology Solutions
- Michele Lau – EVP & Chief Legal Officer
- Stanton McComb – President, Medical-Surgical



# Balfour Capital Group McKesson Corporation

## 4. Revenue

For the fiscal year ending March 31, 2024, McKesson reported:

- Annual Revenue: \$308.9 billion, an increase of 12% year-over-year.

In the third quarter of fiscal 2025, the company reported:

- Quarterly Revenue: \$95.29 billion, a 17.8% increase year-over-year.

## 5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for McKesson:

- UBS: Maintained a "Buy" rating with a price target of \$805.00.

Overall, McKesson has an average brokerage recommendation (ABR) of 1.47, indicating a consensus between "Strong Buy" and "Buy".

## 6. Analyst Sentiment Summary

Analyst sentiment towards McKesson is generally positive:

- Consensus Rating: Strong Buy
- Based on: 13 Wall Street analysts' ratings.

Additionally, blogger sentiment is more bullish compared to other stocks in the healthcare sector.

## 7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months:

- Insider Sales: 186,593 shares sold, totaling approximately \$89 million.
- Insider Purchases: No significant insider purchases reported in the past 6 months.